Results 21 to 30 of about 90,679 (311)
Toxins, 2022 Despite antivenoms being the only established specific treatment for neuromuscular paralysis arising from snake envenoming, their ability to reverse the post-synaptic neurotoxicity in snake envenoming is poorly understood.
Tam M. Huynh +3 more
doaj +1 more source
Behavioral Tests in Neurotoxin-Induced Animal Models of Parkinson’s Disease
Antioxidants, 2020 Currently, neurodegenerative diseases are a major cause of disability around the world. Parkinson’s disease (PD) is the second-leading cause of neurodegenerative disorder after Alzheimer’s disease.
Maruthi Prasad E, Shih-Ya Hung
semanticscholar +1 more source
Journal of Cosmetic Dermatology, 2020 The literature on botulinum neurotoxin type A (BoNT‐A) is extensive, often contradictory, and confounded by a competitive market of products and research attempting to distinguish brand individuality.
M. Nestor +2 more
semanticscholar +1 more source
Cerebral Complications of Snakebite Envenoming: Case Studies
Toxins, 2022 There are an estimated 5.4 million snakebite cases every year. People with snakebite envenoming suffer from severe complications, or even death. Although some review articles cover several topics of snakebite envenoming, a review of the cases regarding ...
Yu-Kai Huang +5 more
doaj +1 more source
Toxins, 2021 Naja atra, also known as Taiwanese cobra, is one of the most prevalent venomous snakes in Taiwan. Clinically, freeze-dried neurotoxic antivenom (FNAV) produced from horses by Taiwan Centers for Disease Control (CDC) has been the only approved treatment ...
Chien-Chun Liu +6 more
doaj +1 more source
Botulinum Neurotoxin for the Treatment of Neuropathic Pain
Frontiers in Neurology, 2020 Botulinum neurotoxin is widely used for the treatment of central and peripherical neurological conditions. Initially used to treat strabismus, over the years its use has been expanded also to spasticity and other neurological disorders.
G. Egeo, L. Fofi, P. Barbanti
semanticscholar +1 more source
Recombinant botulinum neurotoxin serotype A1 in vivo characterization
Pharmacology Research & Perspectives, 2021 Clinically used botulinum neurotoxins (BoNTs) are natural products of Clostridium botulinum. A novel, recombinant BoNT type A1 (rBoNT/A1; IPN10260) has been synthesized using the native amino acid sequence expressed in Escherichia coli and has previously
Cindy Périer +13 more
doaj +1 more source
Breaking down the cellular responses to type I interferon neurotoxicity in the brain
Frontiers in Immunology, 2023 Since their original discovery, type I interferons (IFN-Is) have been closely associated with antiviral immune responses. However, their biological functions go far beyond this role, with balanced IFN-I activity being critical to maintain cellular and ...
Barney Viengkhou, Markus J. Hofer
doaj +1 more source
Historical Perspectives and Guidelines for Botulinum Neurotoxin Subtype Nomenclature
Toxins, 2017 Botulinum neurotoxins are diverse proteins. They are currently represented by at least seven serotypes and more than 40 subtypes. New clostridial strains that produce novel neurotoxin variants are being identified with increasing frequency, which ...
M. Peck +24 more
semanticscholar +1 more source
Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
Frontiers in Neuroscience, 2023 Immunotherapy is a promising method for cancer treatment. Among them, immune checkpoint inhibitors targeting PD-1/PD-L1 are increasingly used for certain cancers.
Yanting Zhou, Hongyan Li
doaj +1 more source